Norgine is working towards full compliance with Transparantie Zorg, CGR and EFPIA requirements to report payments and transfers of value to healthcare professionals and healthcare organisations.

Please click on the following links to have a view of the recent transfers of value and our methodology for collecting the same. (Dutch version) (English version)

Methodology note: 2020, 2019, 2018

The costs for research and development (R&D) have not been incorporated in the above mentioned transparency register. Nonetheless, in order to be as transparent as possible it has been the decision by EFPIA that European pharma companies should publish these R&D costs made in the respective countries on their website in an aggregate manner.  In 2020, there was no R&D costs for Norgine in the Netherlands. In the Netherlands, the R&D work and thus the aggregated amount is usually rather limited as most R&D is performed internationally outside the Netherlands.

Should you have any query related to the reported transfers of value, please contact us via contact details as listed towards the end of our methodology note.